Revenio: Let's investigate before we jump to any further conclusions
A profit warning weighed on the stock yesterday, which was largely justified as earnings growth turned negative. However, on current information, we expect the weakness to be temporary and the company to return to earnings growth next year. With this, the valuation (2024e EV/EBIT 19x) is reasonable after the collapse. However, the surprisingly sharp deceleration keeps risks elevated and raises concerns, which we will address in the Q2 report.
Login required
This content is only available for logged in users
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures03.08.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 97.0 | 97.5 | 109.6 |
growth-% | 23.10 % | 0.52 % | 12.41 % |
EBIT (adj.) | 30.9 | 26.3 | 32.6 |
EBIT-% (adj.) | 31.84 % | 26.99 % | 29.72 % |
EPS (adj.) | 0.86 | 0.74 | 0.95 |
Dividend | 0.36 | 0.31 | 0.45 |
Dividend % | 0.93 % | 1.14 % | 1.64 % |
P/E (adj.) | 44.64 | 37.05 | 29.10 |
EV/EBITDA | 30.64 | 24.60 | 19.67 |